Journal of Respirology Publishes Clinical Trial Data Demonstrating the Benefits of Noah Medical’s Galaxy System
27 Junio 2024 - 1:39PM
Medical robotics innovator Noah Medical today announced the final
results from its FRONTIER Study, the platform’s first-in-human
clinical trial testing the “Tool-in-Lesion” accuracy of its Galaxy
System™, are now available for review in the Official Journal of
the Asian Pacific Society of Respirology. The study found that the
robotic platform’s TiLT+ Technology™ achieves 100% successful
navigation to small lesions in the periphery, 89.5 (strict) to
94.7% (intermediate) diagnostic yield and 100% tool-in-lesion
accuracy.
“We are excited that the final clinical results are published
after peer review as the latest demonstration of the Galaxy
System’s incredible promise, having also recently shared initial
hospital-led findings from over one thousand successful procedures
in health systems across the United States,” said Jian Zhang, Noah
Medical CEO. “After years of working with leading pulmonologists to
understand and address the challenges of diagnosing lung cancer
with existing technologies, the Galaxy System’s groundbreaking
technology makes it easier than ever to locate and diagnose this
deadly disease.”
The FRONTIER Study clinical trial was
conducted by pioneering Interventional Pulmonologists at Macquarie
University Hospital in Sydney, Australia and showed the Galaxy
System’s ability to successfully reach peripheral pulmonary nodules
ensuring the safety of patients during the bronchoscopy procedure
and up to seven days post-procedure.
“The final results of this trial reinforce all of our earlier
findings to accurately navigate to and biopsy small peripheral lung
nodules,” said Tajalli Saghaie, M.D., co-principal investigator of
the FRONTIER study. “It has also been reassuring to hear of similar
results in the field from physicians worldwide since the Galaxy
system’s rollout last year.”
Preliminary data from the clinical trial were previously
presented to a standing-room-only crowd at the American Association
of Bronchology and Interventional Pulmonology’s annual conference
(AABIP 2023) in Chicago. Just last month, Noah Medical also shared
new field data demonstrating the power of Galaxy’s integrated
imaging to overcome CT-to-body divergence in navigated
bronchoscopy.
To learn more about Noah Medical and the Galaxy System, please
visit noahmed.com.
About Galaxy SystemDesigned in collaboration
with physicians, the Galaxy System represents the next generation
in lung navigation robotics. Its proprietary TiLT Technology
provides real-time lesion updates to overcome existing problems,
such as CT to body divergence or image discrepancies as the body
moves, that result in a lack of definitive tissue biopsy. The
Galaxy System’s proprietary StrikePoint technology revolutionizes
robotic lung biopsy by providing precise distance to target using
just the c-arm technologies already available in hospitals. This
integrated robotic navigation system also employs a single-use
bronchoscope and has the smallest footprint of any commercial lung
navigation robotic platform, allowing for more efficient procedures
with a reduced risk of contamination and patient infection.
About Noah Medical
Noah Medical is building the future of medical robotics, and the
Galaxy System is Noah Medical’s first commercial robotic system.
The company’s mission is to deliver adoptable clinical solutions
through innovative endoluminal technologies to enhance the quality
of life for patients globally. Based in Silicon Valley and backed
by well-known institutional investors, our incredibly talented team
of engineers, innovators and industry leaders bring years of
experience from the top robotics, medical device and healthcare
companies in the world.
Media Contact:Jen SipeNoah Medicalpress@noahmed.com